Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

PhoenixBio Yönetim

Yönetim kriter kontrolleri 2/4

PhoenixBio's CEO'su Takashi Shimada, Jan2018 tarihinde atandı, in görev süresi 6.75 yıldır. şirketin hisselerinin 1.27% doğrudan sahiptir ve bu hisselerin değeri ¥ 22.95M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.3 yıl ve 5.3 yıldır.

Anahtar bilgiler

Takashi Shimada

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.8yrs
CEO sahipliği	1.3%
Yönetim ortalama görev süresi	10.3yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Takashi Shimada (65 yo)

6.8yrs

Görev süresi

Takashi Shimada serves as the President and CEO at PhoenixBio Co. Ltd. since June 2018 and has been its Representative Director. He served as Executive Vice President and Vice Chairman of the Board at Phoe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kenji Kuramoto	Executive Chairman	18.9yrs	Veri yok	1.23% ¥ 21.8m
Takashi Shimada	President	6.8yrs	Veri yok	1.27% ¥ 22.6m
Yasuhiro Tamura	Senior MD	10.3yrs	Veri yok	0.74% ¥ 13.2m
Tomoyo Mukaiya	Executive Director of Research & Development and Director	10.3yrs	Veri yok	0.63% ¥ 11.1m

10.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim: 6190 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kenji Kuramoto	Executive Chairman	18.9yrs	Veri yok	1.23% ¥ 21.8m
Takashi Shimada	President	no data	Veri yok	1.27% ¥ 22.6m
Yasuhiro Tamura	Senior MD	no data	Veri yok	0.74% ¥ 13.2m
Tomoyo Mukaiya	Executive Director of Research & Development and Director	no data	Veri yok	0.63% ¥ 11.1m
Masatsugu Ueda	Auditor	5.3yrs	Veri yok	0.012% ¥ 218.4k
Yoshinori Fujii	Independent Outside Director	8.3yrs	Veri yok	Veri yok
Hiromi Okano	Auditor	5.3yrs	Veri yok	Veri yok
Motoyasu Ueno	External Auditor	2.3yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6190 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

PhoenixBio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024

Less than half of directors are independent

PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022

Less than half of directors are independent

Recent updates

PhoenixBio Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: EPS: JP¥5.71 (vs JP¥11.56 in 1Q 2024)

Investor sentiment deteriorates as stock falls 16%

PhoenixBio Co., Ltd. to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings released: EPS: JP¥6.88 (vs JP¥145 in FY 2023)

PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024

PhoenixBio Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024

Third quarter 2024 earnings released: JP¥3.45 loss per share (vs JP¥10.86 profit in 3Q 2023)

New minor risk - Share price stability

PhoenixBio Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: JP¥4.05 loss per share (vs JP¥76.11 profit in 2Q 2023)

PhoenixBio Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: EPS: JP¥11.56 (vs JP¥31.15 in 1Q 2023)

PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: JP¥145 (vs JP¥117 loss in FY 2022)

Third quarter 2023 earnings released: EPS: JP¥10.86 (vs JP¥9.37 loss in 3Q 2022)

PhoenixBio Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: EPS: JP¥76.11 (vs JP¥58.69 loss in 2Q 2022)

Less than half of directors are independent

PhoenixBio Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥31.15 (vs JP¥19.46 in 1Q 2022)

PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022

Full year 2022 earnings released: JP¥117 loss per share (vs JP¥73.60 loss in FY 2021)

Less than half of directors are independent

PhoenixBio Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥58.69 loss per share (vs JP¥44.41 loss in 2Q 2021)

Full year 2021 earnings released: JP¥73.60 loss per share (vs JP¥142 loss in FY 2020)

PhoenixBio Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021

Third quarter 2021 earnings released: JP¥24.33 loss per share (vs JP¥9.54 loss in 3Q 2020)

New 90-day low: JP¥582

New 90-day low: JP¥616

PhoenixBio Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş